The state of Ohio currently has 113 active clinical trials seeking participants for Breast Cancer research studies. These trials are conducted in various cities, including Cincinnati, Columbus, Cleveland and Dayton.
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Women With a PI3K Alteration and HR+/Her2- Breast Cancer
NCT05455619
Recruiting
This is a Phase 1b/2, open-label, parallel-arms pilot study in post-menopausal women with hormone receptor positive (HR+), HER2- advanced or metastatic breast cancer with an alteration in the PI3K pathway, including a mutation of the PIK3CA gene, PTEN loss, or AKT1 mutation, designed to determine the safety of evexomostat (SDX-7320) plus standard of care treatment alpelisib (BYL-719) or capivasertib and fulvestrant (each combined, the 'triplet therapy'), to measure the severity and number of hyp... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/23/2025
Locations: Toledo Clinic Cancer Center, Toledo, Ohio
Conditions: HR+/HER2-negative Breast Cancer, Metastatic Breast Cancer
Register for Updates
Trial of 225Ac-DOTATATE (RYZ101) in Subjects with ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
NCT06590857
Recruiting
Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) in subjects with ER+, HER2-negative unresectable or metastatic breast cancer expressing SSTRs.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/15/2025
Locations: Research Facility, Cleveland, Ohio
Conditions: Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer
Register for Updates
DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
NCT04567420
Recruiting
A randomized, Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, Estrogen Receptor positive, HER-2 negative breast cancer (DARE)
Gender:
ALL
Ages:
All
Trial Updated:
01/10/2025
Locations: The Ohio State University Wexner Medical Center James Cancer Hospital, Columbus, Ohio
Conditions: Breast Cancer
Register for Updates
T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
NCT04457596
Recruiting
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: Aultman Alliance Community Hospital, Alliance, Ohio +66 locations
Conditions: Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Synchronous Bilateral Breast Carcinoma
Register for Updates
Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
NCT03556228
Recruiting
This is a multicenter, open-label, Phase 1 study of orally administered VMD-928 in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curative therapy exists
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
01/08/2025
Locations: Taylor Cancer Research Center, Maumee, Ohio
Conditions: Mesothelioma, Ovarian Cancer, Adenoid Cystic Carcinoma, Cervical Cancer, Any Solid Tumors Progressed After a Prior Immunotherapy, Thymic Carcinoma, Bladder Cancer, Pancreatic Cancer, Head and Neck Carcinoma, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Sarcoma, Esophageal Cancer, Uterine Cancer, Thymoma, Appendiceal Cancer, Olfactory Neuroblastoma
Register for Updates
Patient Recall of Cancer Screening and Diagnosis
NCT05014295
Recruiting
The purpose of this research is to try to better understand how much information relating to cancer screening and diagnoses that people can recall on their own and to better understand how to help people get better information. In this study, investigators will see if giving time or other resources help individuals remember more and more accurate details about their cancer screening and care.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/06/2025
Locations: Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: Breast Cancer, Prostate Cancer
Register for Updates
Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells with or Without Naxitamab (Danyelza) for the Treatment of Patients with Metastatic, GD2 Expressing, HER2 Negative Breast Cancer
NCT06026657
Recruiting
This phase Ib/II trial tests the safety, best dose and how well gemcitabine and ex vivo expanded allogenic universal donor TGFBi NK cells with or without naxitamab work for the treatment of patients with GD2 expressing, HER2 negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Gemcitabine is a chemotherapy drug that blocks the cells from making deoxyribonucleic acid (DNA) and may kill cancer cells. TGFBi NK cells are manufact... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/06/2025
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma
Register for Updates
Inspiratory Muscle Training in Obese Breast Cancer Survivors
NCT05193149
Recruiting
The investigators propose a randomized controlled trial to determine the effectiveness of inspiratory muscle training in improving exercise tolerance among stage 0-III obese breast cancer survivors.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/27/2024
Locations: The Ohio State University, Columbus, Ohio
Conditions: Cancer Survivors, Obesity, Breast Cancer
Register for Updates
A Phase 1/1b Study of IAM1363 in HER2 Cancers
NCT06253871
Recruiting
This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/24/2024
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer, HER2 + Breast Cancer, Brain Metastases from Solid Tumors, Brain Metastases from HER2 and Breast Cancer, CNS Metastases, HER2-Positive Solid Tumors, NSCLC (non-small Cell Lung Cancer), HER2-positive Bladder Cancer, HER2-positive Colorectal Cancer, HER2 + Gastric Cancer, HER2-positive Gastroesophageal Cancer
Register for Updates
Integrated Cancer Repository for Cancer Research
NCT02012699
Recruiting
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer... Read More
Gender:
ALL
Ages:
Between 19 years and 110 years
Trial Updated:
12/18/2024
Locations: Aultman Alliance Community Hospital, Alliance, Ohio +1 locations
Conditions: Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer, Thymus Cancer, Colon Cancer, Rectal Cancer, Anal Cancer, Bile Duct Cancer, Duodenal Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Small Intestine Cancer, Peritoneal Surface Malignancies, Familial Adenomatous Polyposis, Lynch Syndrome, Bladder Cancer, Kidney Cancer, Penile Cancer, Prostate Cancer, Testicular Cancer, Ureter Cancer, Urethral Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Lip Cancer, Oral Cavity Cancer, Nasopharyngeal Cancer, Oropharyngeal Cancer, Paranasal Sinus Cancer, Nasal Cavity Cancer, Salivary Gland Cancer, Skin Cancer, Mesothelioma, Breast Cancer, Leukemia, Melanoma, Sarcoma, Unknown Primary Tumor, Multiple Myeloma, Ovarian Cancer, Endometrial Cancer, Vaginal Cancer, Neuroendocrine Tumors, Plasma Cell Dyscrasia, Healthy Control, Gastrointestinal Stromal Tumors, Central Nervous System Tumor, Central Nervous System Cancer
Register for Updates
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
NCT05501886
Recruiting
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: University Hospitals Cleveland Medical Center, Cleveland, Ohio +1 locations
Conditions: Breast Cancer
Register for Updates
A Study of ADRX-0706 in Select Advanced Solid Tumors
NCT06036121
Recruiting
The primary purpose of this study is to assess the safety, tolerability, and pharmacokinetics, and to identify the optimal dose of ADRX-0706 in patients with select advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/13/2024
Locations: The Ohio State University Wexner Medical Center, Hillard, Ohio
Conditions: Solid Tumors, Triple Negative Breast Cancer (TNBC), Urothelial Cancer, Cervical Cancer
Register for Updates